Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 6/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.39 |
| ▸ | LDHB | P07195 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.39 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.38 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | CDK9 | P50750 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9949269 | 1.00 | GSK3B (0.39) | GSK3BDYRK1ALDHALDHBCCNT1 | |
| SCHEMBL9949270 | 0.84 | CCNT1 (0.39) | GSK3BDYRK1ALDHALDHBCCNT1 | |
| SCHEMBL9949679 | 0.84 | CCNT1 (0.39) | GSK3BDYRK1ALDHALDHBCCNT1 | |
| SCHEMBL10179191 | 0.78 | CCNT1 (0.48) | CCNT1CDK9 | |
| SCHEMBL10285397 | 0.77 | CDK9 (0.59) | GSK3BDYRK1ACCNT1CDK9 | |
| SCHEMBL10285384 | 0.77 | CDK9 (0.59) | GSK3BDYRK1ACCNT1CDK9 | |
| SCHEMBL9949448 | 0.76 | CCNT1 (0.55) | GSK3BDYRK1ACCNT1 | |
| SCHEMBL9949605 | 0.76 | CCNT1 (0.57) | CCNT1CDK9 | |
| SCHEMBL9949639 | 0.76 | KDM4E (0.41) | CCNT1FFAR4 | |
| SCHEMBL9950120 | 0.76 | KDM4E (0.41) | CCNT1FFAR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165306-A1 | PYRAZINYLPYRIDINES USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK4, CDK1, CCNI | GSK3B 1536/4885DYRK1A 1864/4885LDHA 2579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.